RBC Capital Reinstates Outperform on Alexion Pharmaceuticals, Announces $135 Price Target

RBC Capital analyst Kennen MacKay reinstates Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and announces $135 price target.

Benzinga · 01/31/2020 15:24

RBC Capital analyst Kennen MacKay reinstates Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and announces $135 price target.